Article thumbnail
Location of Repository

Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics

By John S Vorhies and John J Nemunaitis


Aptamers are nucleic acid ligands which have been validated to bind to epitopes with a specificity similar to that of monoclonal antibodies. Aptamers have been primarily investigated for their direct function in terms of inhibition of protein targets; however, recent evidence gives reason to actively explore aptamers as targeting moieties for delivery of anticancer therapeutics. Many aptamers have been developed to bind to extracellular membrane domains of proteins overexpressed on cancer cells and have the potential to be modified for use in targeting cancer therapeutics. The use of DNA vector-based short hairpin RNA (shRNA) for RNA interference (RNAi) is a precise means for the disruption of target gene expression but its clinical usage in cancer is limited by obstacles related to delivery into cancer cells. Nucleic acid aptamers are attractive candidates for targeting of shRNA therapies. Their small size, ease of production and modification, and high specificity are valued attributes in comparison to other targeting moieties currently being tested. Here we review the development of aptamers directed to PSMA, Nucleolin, HER-3, RET, TN-C, and MUC1 and focus on their potential for use in targeting of shRNA-based cancer therapeutics

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2005). A novel method to generate aptamers against recombinant targets displayed on the cell surface. Nucleic Acids Symp Ser (Oxf),
  2. (1995). Alternatively spliced variants of prostate-specifi c membrane antigen RNA: ratio of expression as a potential measurement of progression.
  3. (1991). Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodefi ciency virus type 1 transactivation.
  4. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo.
  5. (1999). Antiproliferative activity of G-rich oligonucleotides correlates with protein binding.
  6. (2002). Antiproliferative activity of Gquartet-forming oligonucleotides with backbone and sugar modifi cations.
  7. (2004). Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.
  8. (2006). Aptamer mediated siRNA delivery.
  9. (2005). Aptamers against extracellular targets for in vivo applications.
  10. (2006). Aptamers come of age – at last.
  11. (1991). Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifi es the tissue distribution.
  12. (2005). Automated in vitro selection and microarray applications for functional RNA sequences.
  13. (2002). Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer.
  14. (1999). Biological and biochemical properties of Ret with kinase domain mutations identifi ed in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
  15. (2003). Biophysical and biological properties of quadruplex oligodeoxyribonucleotides.
  16. (2006). Cell type-specifi c delivery of siRNAs with aptamer-siRNA chimeras.
  17. (1995). Chemical modifi cation of hammerhead ribozymes. Catalytic activity and nuclease resistance.
  18. (1997). Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z).
  19. (2005). Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and infl amed tissues.
  20. (2003). Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line.
  21. (1998). Current evaluation of the tissue localization and diagnostic utility of prostate specifi c membrane antigen.
  22. (2004). Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3. Nucleic Acids Symp Ser (Oxf),
  23. (2000). Developing aptamers into therapeutics.
  24. (2000). Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers.
  25. (1989). Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer.
  26. (1997). Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and Atype cyclin-CDK complexes.
  27. (2005). Direct in vitro selection of a 2′-O-methyl aptamer to VEGF.
  28. (2006). Discovery and development of anticancer aptamers.
  29. (2002). Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers.
  30. (1995). Diversity of oligonucleotide functions. Annu Rev Biochem,
  31. (2006). DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers.
  32. (1992). Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues.
  33. (1998). Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
  34. (1994). Expression of the prostatespecifi c membrane antigen.
  35. (2006). Extended phase I study of AS1411 in renal and non-small cell lung cancers. J Clin Oncol, 24[18S(June 20 Supplement)]:13098.
  36. (2000). Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood.
  37. (2002). Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev,
  38. (2007). for the Macugen AMD Study Group.
  39. (2007). Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
  40. (2007). Functions of the histone chaperone nucleolin in diseases. Subcell Biochem,
  41. (1988). Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplifi cation of the v-erbA homologue.
  42. (2006). HIV-1 inactivation by nucleic acid aptamers. Front Biosci,
  43. (2000). Human MUC1 mucin: a multifaceted glycoprotein.
  44. (2002). Identifi cation and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specifi c membrane antigen.
  45. (1990). In vitro selection of RNA molecules that bind specifi c ligands.
  46. (1993). In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits.
  47. (2001). In vivo recognition of an RNA aptamer by its transcription factor target.
  48. (1988). Induction of tenascin in healing wounds.
  49. (2003). Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
  50. (2001). Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
  51. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
  52. (2000). Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.
  53. (1998). Liposome-anchored vascular endothelial growth factor aptamers.
  54. (2007). Methods developed for SELEX.
  55. (1999). Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights.
  56. (1987). Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res,
  57. (1998). MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma. Dis Colon Rectum,
  58. (2007). Mucin expression profi le in Barrett’s, dysplasia, adenocarcinoma sequence in the esophagus.
  59. (1997). Mucin-producing adenocarcinoma of the lung, with special reference to goblet cell type adenocarcinoma: immunohistochemical observation and Ki-ras gene mutation.
  60. (2004). Mucins in cancer: protection and control of the cell surface.
  61. (2000). Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.
  62. (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
  63. (2005). Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS
  64. (2005). New NTP analogs: the synthesis of 4′-thioUTP and 4′-thioCTP and their utility for SELEX.
  65. (2003). Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels.
  66. (1987). Nucleolin, the major nucleolar protein of growing eukaryotic cells: an unusual protein structure revealed by the nucleotide sequence.
  67. (2005). Nucleolin: acharan sulfatebinding protein on the surface of cancer cells.
  68. (1990). Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer.
  69. (1990). Overexpression of TAR sequences renders cells resistant to human immunodefi ciency virus replication.
  70. (2004). Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells.
  71. (2000). Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys.
  72. (2006). Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor.
  73. (2005). Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specifi c membrane antigen, in patients with androgen-independent prostate cancer.
  74. (1995). Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fi broblast growth factor.
  75. (2005). Potential oncogenic action of tenascin-C
  76. (1998). Prostate specifi c membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
  77. (2007). Radiolabelled aptamers for tumour imaging and therapy.
  78. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa.
  79. (2007). RNA aptamers directed to discrete functional sites on a single protein structural domain.
  80. (2006). Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface.
  81. (2003). Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identifi ed by a novel approach: tailored-SELEX.
  82. (2004). Small molecule toxins targeting tumor receptors.
  83. (1999). Structure and functions of nucleolin.
  84. (1989). Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer.
  85. (2006). Successful in vivo tumor targeting of prostate-specifi c membrane antigen with a highly effi cient J591/PEI/DNA molecular conjugate.
  86. (2004). Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells.
  87. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.
  88. (2006). Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo.
  89. (2005). Targeted polymers for gene delivery. Expert Opin Drug Deliv,
  90. (1995). Tenascin expression in astrocytomas correlates with angiogenesis.
  91. (1991). Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications.
  92. (2001). Tenascin-C aptamers are generated using tumor cells and purified protein.
  93. (2006). Tenascin-C induced signaling in cancer.
  94. (1989). Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol,
  95. (2000). The AgNORs.
  96. (2002). The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affi nity receptor.
  97. (2000). The cell-surfaceexpressed nucleolin is associated with the actin cytoskeleton.
  98. (2001). The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specifi c cytotoxic T-lymphocytes.
  99. (1995). The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells.
  100. (2002). The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer.
  101. (2004). Tumor target prostate specifi c membrane antigen (PSMA) and its regulation in prostate cancer.
  102. (2006). Tumor targeting by an aptamer.
  103. (2005). Update on the fi rst phase I study of AGRO100 in advanced cancer.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.